Risk-adapted prostate-specific antigen screening guidelines
Risk-adapted prostate-specific antigen screening guidelines has been studied in 1 paper since 2026: 1 trial in people; 1 in the past year. The newest paper, Feb 28, 2026: “A trial of risk-adapted prostate cancer screening in a federally supported health center network serving a high-risk population”.
1 paper studies it3 findingsUpdated
See all 1 papers on risk-adapted prostate-specific antigen screening guidelines
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“PSA screening following encounters increased from 18.7 to 33.0 per 100 patients (Δ = 14.3; 95% CI, 12.4-16.1) with odds ratio = 2.43 (95% CI, 2.17-2.71)”
None of its findings points the other way.
- 1 lab in 1 country
- Human trial1
Studies in people
1 study gave risk-adapted prostate-specific antigen screening guidelines to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
up: Increases prostate-specific antigen screening18.7 to 33.0 per 100 patients, OR 2.43 (95% CI, 2.17-2.71) up: Increases prostate biopsy incidence0.57 to 0.92 per 100 (Δ = 0.35; 95% CI, -0.03 to 0.75) up: Increases prostate cancer2.7-fold (0.25 to 0.68 per 100, p = .007) | Trial15-month | 4,252 peopleMenage 35 and overMidlife adults; Older adults; primary care encounters in clinics serving Chicago communities with high PCa mortality and Black population density | Cancer, Feb 28, 2026 |
What did studies of risk-adapted prostate-specific antigen screening guidelines find?
3Studies of risk-adapted prostate-specific antigen screening guidelines measured 3 outcomes: prostate cancer, prostate biopsy incidence and prostate-specific antigen screening.
Prostate cancer
upin humans1
1 study
Prostate cancer
upin humans1
Risk-adapted prostate-specific antigen screening guidelines increase prostate cancer in humans (primary care encounters) (2.7-fold (0.25 to 0.68 per 100, p = .007)).
“Total PCa incidence rose 2.7-fold (0.25 to 0.68 per 100, p = .007), with incidence of cancer beyond grade group 1 increasing 3-fold (p = .008).”
Human trialprimary care encounters15-monthmalesn = 4,252
Cancer
Prostate biopsy incidence
upin humans1
1 study
Prostate biopsy incidence
upin humans1
Risk-adapted prostate-specific antigen screening guidelines increase prostate biopsy incidence in humans (primary care encounters) (0.57 to 0.92 per 100 (Δ = 0.35; 95% CI, -0.03 to 0.75)).
“Biopsy incidence increased from 0.57 to 0.92 per 100 (Δ = 0.35; 95% CI, -0.03 to 0.75), with PCa prevalence at biopsy increasing from 43% to 74%.”
Human trialprimary care encounters15-monthmalesn = 4,252
Cancer
Prostate-specific antigen screening
upin humans1OR 2.43
1 study
Prostate-specific antigen screening
upin humans1OR 2.43
Risk-adapted prostate-specific antigen screening guidelines increase prostate-specific antigen screening in humans (18.7 to 33.0 per 100 patients, OR 2.43 (95% CI, 2.17-2.71)).
“PSA screening following encounters increased from 18.7 to 33.0 per 100 patients (Δ = 14.3; 95% CI, 12.4-16.1) with odds ratio = 2.43 (95% CI, 2.17-2.71)”
Human trialprimary care encounters in clinics serving Chicago communities with high PCa mortality and Black population density15-monthmalesn = 4,252
Cancer